India’s drug patent policy has been slammed by US companies who are insisting that action be taken in order to improve trade relations.
A federal judge has denied AstraZeneca’s motions to dismiss claims challenging its pay-for-delay deals with three generic pharmaceutical companies in connection to heartburn drug Nexium.
The US District Court for the District of New Jersey has found in favour of Teva Pharmaceutical Industries Ltd in its patent infringement case with Mylan over Parkinson’s disease drug Azilect.
Drug company Watson Laboratories (Actavis) has notified rival Ranbaxy Laboratories that it has applied to sell a generic version of anti-acne product Absorica in the US.
Austria has become the first country in the EU to ratify consent to the Unified Patent Court.
Eli Lilly has begun its defence of a patent covering lung cancer drug Alimta against generic companies including Teva, Barr Laboratories and APP Pharmaceuticals.
US-based Horizon Pharma Inc agreed on August 22 to settle its patent dispute over arthritis drug Duexis with generic maker Par Pharmaceutical Companies.
On August 8 the IPAB revoked another patent owned by a Western pharmaceutical company – this time related to Allergan’s eye drug Combigan.
The Intellectual Property Appellate Board in Chennai has cancelled two trademarks associated with versions of Viagra.
The Court of Appeal for England and Wales has upheld the Patent Court’s decision that Teva Pharmaceutical Industries’ UK patent 762,888, relating to the multiple sclerosis drug Copaxone, is valid.